readthroughSign in
Nov 13, 2026Quarterly update

Biofrontera reports Q3 2026 results after Ameluz sBCC approval and ITC lamp ruling

FDA cleared Ameluz for superficial basal cell carcinoma and customs regulators allowed Biofrontera's redesigned XL-C lamp back into the US, as quarterly revenue rose 30%.

Biofrontera Inc. reported financial results for the quarter ended September 30, 2026, alongside two regulatory developments. On September 9, 2026, the FDA approved Ameluz for the treatment of Superficial Basal Cell Carcinoma, making Ameluz plus Red-Light the first and only photodynamic therapy approved for cancerous skin tumors.1 Five days later, US Customs and Border Protection ruled that the re-designed XL-C lamp did not violate the ITC order and could be imported for use in the US market.1

CEO Hermann Luebbert said the company is readying commercial launch of the new indication and has moved to widen its label. He said the company is preparing to begin commercializing Ameluz for sBCC later in the fourth quarter and into the first quarter of 2027, and that in October it submitted a supplemental New Drug Application seeking to expand the Ameluz label for actinic keratosis to the extremities, neck and trunk.1 He added that both new indications would be served by the lamps and sales force already in place.1

On the financials, net product revenue was $9.1 million, up 29.8% from $7.0 million a year earlier.1 Gross margin was 74.4%, versus 70.7% a year earlier, which the company attributed to the lower Ameluz cost structure established after the Biofrontera AG transaction closed in October 2025, partly offset by ITC-related inventory write-downs and higher lamp and device costs.1 Net loss was $6.4 million, or $(0.42) per share, compared with $6.6 million, or $(0.62) per share, a year earlier.1

For the nine months, revenue was $31.2 million, up 26.6% from $24.6 million.1 On the balance sheet, cash and cash equivalents were $3.2 million as of September 30, 2026, compared with $6.4 million at December 31, 2025.1 Outstanding debt consisted of $4.7 million of convertible notes maturing in November 2027, with no bank or other term debt.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.